{"schema_version":"secwatch.filing_event.v1","accession":"0001438533-23-000006","form_type":"8-K","ticker":"TVTX","cik":"0001438533","company_name":"Travere Therapeutics, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.001434+00:00","generated_at":"2026-06-19T02:22:50.773649+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Travere reports Q4 2022 net loss $65.8M; FDA granted accelerated approval for FILSPARI in IgAN","bullets":["Net product sales $52.3M in Q4 2022 vs $54.6M in Q4 2021; full year $200.5M vs $210.8M.","Net loss $65.8M ($1.03 per share) in Q4 2022 vs $51.6M ($0.84) in Q4 2021; full year loss $278.5M.","Cash and marketable securities $450.2M as of Dec 31, 2022.","FDA granted accelerated approval of FILSPARI (sparsentan) for IgAN on Feb 17, 2023; commercial launch expected week of Feb 27.","Topline data from DUPLEX Study (FSGS) expected Q2 2023; EMA decision on sparsentan for IgAN expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001438533-23-000006","json":"https://secwatch.observer/filing/0001438533-23-000006.json","markdown":"https://secwatch.observer/filing/0001438533-23-000006.md","text":"https://secwatch.observer/filing/0001438533-23-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000006/0001438533-23-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000006/tvtx-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:22:50.773649+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7fdb642f973201775ed25bf79a5ad16c0e6a1a87","claim":"Travere Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue $55.9 million, net income ($65.8 million, or $1.03 per basic share).","evidence_excerpt":"confirmatory endpoints in the ongoing Phase 3 PROTECT Study of sparsentan in IgAN expected in the fourth quarter of 2023 • Total revenue for the fourth quarter of 2022 was $55.9 million, consisting of $52.3 million in net product sales and $3.5 million in licensing and collaboration revenue • Total revenue for the full year 2022 was $212.0 million, consisting of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1438533/000143853323000006/0001438533-23-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"$55.9 million"},{"label":"Net income","value":"($65.8 million, or $1.03 per basic share)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}